|
Held in conjunction with NGS, SCA, Mass Spec: The Road to Diagnostics
28 Sep 2015, at 19:00 - 21:00 in San Diego, California, USA
Introduction to the Training Course
The embracing of next-generation sequencing (NGS) as a diagnostic tool is rapidly accelerating, bringing new challenges and opportunities for genomic medicine. This course addresses the role of NGS in the diagnostic evaluation of inherited disorders and cancer. Participants will be updated on NGS technologies and introduced to bioinformatics analysis employed in the analysis of multi-gene panels, exomes and genomes. Large scale sequencing of individuals provides an unprecedented insight into the genetic makeup of individuals, posing unique pre- and post-testing issues, including appropriate clinical use, informed consent, and results interpretation and delivery. Key Learning Objectives - Explain the technical basis of NGS
- Relate the clinical utility of gene panels, exome and genome sequencing
- Identify elements of consent, interpretation, and reporting of NGS results
- Explore the trends in the NGS field as it evolves towards a high-value diagnostic
Who Should Attend - Academic researchers embarking on NGS projects
- Biotechnology, Diagnostic, and Pharmaceutical Company researchers leveraging NGS for biomarker analyses, diagnostics development
- Core facilities offering NGS services
- Business development and commercial participants from the biotechnology community seeking a deep understanding of NGS and its potential for biomarker analyses and diagnostics development
All course attendees receive the PowerPoint presentations and associated course presentation materials electronically. These are a valuable resource for business plans, R&D plans, and corporate/investor presentations. All attendees will be served dinner during the course.
|
 Nazneen Aziz, Executive Director, Kaiser Permanente Research Bank
|
